Literature DB >> 1822354

Azathioprine in myasthenia gravis: observations in 41 patients and a review of literature.

J B Kuks1, S Djojoatmodjo, H J Oosterhuis.   

Abstract

We report azathioprine treatment of 41 patients with myasthenia gravis, with a follow-up of more than 3 yr. The data show that azathioprine is effective in controlling the disease, both as a single drug as well as in combination with prednisone. In addition it may be steroid sparing. Older patients derived more benefit from the medicament. Side-effects could be managed fairly well, except for one patient who developed a non-Hodgkin lymphoma. Data from this study do not support the supposition that the therapeutic effect of azathioprine is dependent on macrocytosis. Fluctuations of serum levels of antibodies to the acetylcholine receptor were simultaneous with clinical changes and thus were not of predictive volume for the clinical course.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1822354     DOI: 10.1016/0960-8966(91)90005-d

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  7 in total

1.  Intercommunication between the neuroendocrine and immune systems: focus on myasthenia gravis.

Authors:  Jacqueline Mays; Cherié L Butts
Journal:  Neuroimmunomodulation       Date:  2011-09-22       Impact factor: 2.492

2.  Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis.

Authors:  Ahmad R Abuzinadah; Duaa Jabari; Omar Jawdat; Mamatha Pasnoor; Melanie Glenn; Laura Herbelin; April L McVey; Richard J Barohn; Mazen M Dimachkie
Journal:  J Clin Neuromuscul Dis       Date:  2018-12

3.  Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity.

Authors:  C N Bernstein; L Artinian; P A Anton; F Shanahan
Journal:  Dig Dis Sci       Date:  1994-08       Impact factor: 3.199

Review 4.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

Review 5.  Treatment of Myasthenia Gravis in the Aged.

Authors:  Nuha M Alkhawajah; Joel Oger
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

6.  Current and emerging treatments for the management of myasthenia gravis.

Authors:  Sivakumar Sathasivam
Journal:  Ther Clin Risk Manag       Date:  2011-07-22       Impact factor: 2.423

Review 7.  Current Treatment of Myasthenia Gravis.

Authors:  Mohammed K Alhaidar; Sumayyah Abumurad; Betty Soliven; Kourosh Rezania
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.